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Abstract:
Begun operating in 1992 and today is ready to be bought and to grow massively in the upcoming years. LNA Santé, the fifth French player in the long-term care market, will
be acquired in 2019 in a Private Equity deal and will improve its operations in Europe. This deal is expected to return 3.1x the money invested by the fund and an internal rate
of return of almost 26% with an exit in five years (2023). This successful exit is possible due to an ageing population that is set to increase demand for dependent care which is
reflected in the number of nursing home beds forecasted to double.
By the time of exit, the firm will amount €828 M of revenues and €94 M of EBITDA streaming from consolidation of operations in the current operating countries – France
and Belgium – and an internationalization bet in the Netherlands. It is presumed that this paper will inform how a deal in Private Equity in the long-term care market in Europe
is conducted.
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LNA SANTÉ | INVESTMENT COMMITTEE PAPER
(millions €) 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenues 538,8 716,5 766,1 862,5 822,0 828,2 848,6 871,7 898,6 930,5
% growth 33% 7% 13% -5% 1% 2% 3% 3% 4%
Revenue Levers*
Operational +10,0 +18,3 +18,6 +16,9 +13,0 +13,3 +13,5 +13,7 +13,8
Greenfields - +16,8 +29,2 +5,8 - - - - -
Acquisitions +227,3 +0,2 +0,2 +0,2 +0,2 +0,2 +0,2 +0,2 +0,2
Internationalization +20,4 +2,1 +2,8 +3,8 +5,1 +7,0 +9,5 +13,0 +17,8
Non-core -80,0 12,2 45,5 -67,2 -12,3 - - - -
Organic Growth 2% 5% 6% 3% 2% 2% 2% 2% 2%
Inorganic Growth 31% 2% 6% -7% -1% 1% 1% 2% 2%
Segments
ALF 261,1 450,8 467,4 482,9 499,9 508,3 516,8 525,5 534,4 543,5
% Total Revenues 60% 64% 63% 62% 61% 61% 61% 60% 59% 58%
ACR 137,4 158,8 175,8 206,5 210,6 214,9 219,2 223,6 228,2 232,8
% Total Revenues 28% 22% 23% 24% 25% 26% 26% 26% 26% 27%
Home Care 38,7 96,5 98,9 101,5 104,1 105,5 107,0 108,5 110,0 111,5
% Total Revenues 8% 13% 13% 13% 14% 13% 14% 14% 14% 15%
FORECASTED FINANCIALS|Revenue Levers
LNA will grow 16% its revenues from 2019 to 2023. Inorganic growth is crucial for LNA to diversify its operations and keep growing its 
revenues. In the first three years, both acquisitions and greenfields will be the main drivers 
• Revenue Growth will be 54% from 2018 to 2023 and it will
correspond to a 5 and 7-year CAGR of 9% and 7%. In 2022 there is
a decrease in revenue growth due to the end of revenue stream
from real-estate.
• Operational efficiencies are mainly due a better allocation of beds
(Annex 10). The number of beds per facility ratio increased 7%, 8%
and 5% in ALF France, ACR France and Belgium until 2023. Overall
revenue increase due to pricing are reflected in the operational
lever. The price increased 1,5% a year.
• Greenfields will impact revenues in 2020, 2021 and 2022 with the
construction of 6 new facilities in France. Each construction only
impacts revenues in the year of its launch because in the following
years there won’t be additional facilities.
• Acquisitions will have a higher impact in 2019 with the acquisition
of 2 HC firms in France and an ALF/ACR firm in Belgium.
Acquisitions have a residual impact in revenues of €0,2 M due the
expansion of patients visited in Home Care in France.
• Internationalization to the Netherlands will drive revenues in the
first year with 1 acquisition in ALF segment and with the further
progressive expansion of Home Care segment.
• Non-core revenues** reflect the sale of 1 previous greenfield and
the six new constructions made between 2019 and 2021.
• Inorganic Growth is the main driver of revenue growth in 2019 as a
reflection of the acquisitions made (31%). The following years,
growth is mainly based in organic growth.
• Home Care will account 13% of total revenues in 2023 as a
response to the LNA’s bet in this segment.
Revenue Growth
+ The Levers represent the incremental value that each Investment Thesis brings to the Revenue growth.
** The sale of greenfields was based on the current asset-light strategy of LNA Santé.
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LNA SANTÉ | INVESTMENT COMMITTEE PAPER
(millions €) 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Revenues 538,8 716,5 766,1 862,5 822,0 828,2 848,6 871,7 898,6 930,5
Impact in EBITDA
Revenue Change 9,5 11,7 14,8 2,0 1,7 2,5 3,2 4,7 6,5
Personnel Costs 5,7 0,3 -0,3 2,2 0,2 0,3 0,3 0,1 0,1
% Total Revenues 55% 52% 49% 51% 51% 50% 50% 49% 48%
Rents -1,5 -0,1 0,1 -0,2 -0,1 -0,1 -0,1 -0,1 -0,1
% Total Revenues 29% 31% 30% 34% 35% 36% 37% 37% 38%
Others -2,4 0,0 0,0 0,0 0,0 0,0 0,0 0,0 0,0
% Total Revenues 16% 17% 21% 15% 14% 14% 14% 14% 14%
Change EBITDA 11,4 11,8 14,5 4,0 1,8 2,7 3,5 4,7 6,5
EBITDA 50,2 61,6 73,4 88,0 92,0 93,8 96,5 99,9 104,6 111,1
% EBITDA Margin 9% 9% 10% 10% 11% 11% 11% 11% 12% 12%
ALF Margin 8,9% 9,2% 9,3% 9,4% 9,2% 8,9% 8,6% 8,2% 7,9%
ACR Margin 9,7% 11,6% 14,4% 14,6% 14,7% 14,8% 14,8% 14,8% 14,6%
Home Care Margin 8,0% 9,9% 11,9% 13,8% 14,9% 16,2% 17,8% 19,7% 22,1%
• Personnel Costs are a driver of EBITDA growth due to the
operational improvements in the number of employees per bed.
This ratio improved and decreased 4 pp of revenues until 2023.
• Rents make a big part of LNA’s cost structure and have a
negative impact on the EBITDA margin. With the expansion of
the business, the level of rents as a percentage of revenues will
increase 6 pp until 2023. Rents in France and Belgium are
already known values. In Netherlands the value of rents was
assumed to be the average value spent by square meter in the
long-term care industry.
• Other costs include external expenses and variation in finished
goods assumed to remain constant as a percentage of revenues.
• In the ALF segment the margin will improve 0,3 modest pp until
2023 given that it its a well-established service and the
improvements come with new synergies.
• In the ACR segment margins will grow 5 pp until 2023 given that
it is a service with a track record of higher EBITDA margins. It is
also the segment that LNA has invested more in operational
efficiencies (e.g. more beds per facility).
• The Home Care segment will also see an increase of 6,9 pp in
this margin mainly due to the entrance in Netherlands with a
brand new and efficient model of home service.
EBITDA Margin Growth
FORECASTED FINANCIALS|EBITDA Levers
LNA will increase its EBITDA margin from 9,3% to 11% in 2023. This increase is mainly due to operational efficiencies allied with robust 
revenue growth
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(millions €) 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
CAPEX 12,2 76,3 69,3 33,9 26,6 27,2 27,8 28,6 29,5 30,5
Current Business 12,2 22,8 24,0 25,7 26,6 27,2 27,8 28,6 29,5 30,5
Greenfields 0,7 45,3 8,2 - - - - - -
Acquisitions 44,7 - - - - - - - -
Internacionalization 8,1 - - - - - - - -
Changes NWC 6,8 -6,5 7,4 15,8 -8,4 1,2 3,4 3,8 4,3 4,9
Cash Conversion Cycle 97 69 69 69 69 69 69 69 69 69
Average Collection Period 62 53 53 53 53 53 53 53 53 53
Average Holding Period 76 64 64 64 64 64 64 64 64 64
Average Payable Period 42 47 47 47 47 47 47 47 47 47
• CAPEX: The majority of the investment will be made in 2019 and
2020 with respective expansion CAPEX of €53,5 M and €45,3 M.
• Maintenance CAPEX is approximately 3% of revenues in every
year and includes costs of extending the size of the properties,
the refurbishment of beds and repairs of other assets.
• Greenfields expenditures are all in France and start in 2019 with
1 ALF and 1 ACR construction. Three other constructions are
conducted in 2020 (1 in ALF and 2 in ACR) and 1 more in 2021 (in
ALF). This sort of expenditure takes less investment capacity
from LNA than acquisitions.
• Acquisitions are all made in 2019 so that by the time of exit the
acquired facilities are fully optimized. In total, LNA will make 2
acquisitions in Home Care in France (10 facilities) and will
acquire Vivalto Home in Belgium (24 facilities).
• Internationalization to the Netherlands accounts for the
acquisition of Stepping Stones (12 facilities) and the expansion of
the Home Care model.
• Changes NWC will increase throughout the years, except in the
2019 and 2022. The first is explained by an increase in accounts
payables and the second is explained by the impact of non-core
in overall revenues.
• Cash Conversion Cycle: For the past 4 years the firm has been
decreasing the CCC in a very steep way. Until 2027, LNA Santé
will have improved its CCC and stabilize it at 69 days for the firm
to convert its investments into cash.
CAPEX Expenditures
FORECASTED FINANCIALS|CAPEX Expenditure
The majority of CAPEX investment was made in the first three years in a total amount of €107 M spent in 6 greenfield constructions and 4 
acquisitions
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• For a care home provider to operate and be financially secure in the short to medium term it must generate enough cash to adapt to the industry’s movements and changes. 
• Regulation is a major factor to consider in this industry to safeguard a good financial stability. 
• Furthermore, in the first years, the firm invests aggressively in new investments however, it takes some time for all the new investments to become fully operational. There are some risks 
to take into account, when acquiring and building new facilities, that might impact the firm’s Free Cash Flow generation. 
• The acquired firms are good targets that are assumed to be ready for its acquisition and for the change of operations to LNA Santé. These acquisitions might take more time than expected 
and that would have an impact in the cash flow.
• Furthermore, the Greenfields also take time to construct and to be fully operational. Some delays in constructions would affect, once again, the cash flow generation. 
FORECASTED FINANCIALS|Forecasted Cash Flow
The firm will keep generating a good cash flow from Operations. In the first two years the FCF is subject to large CAPEX investments due 
to the aggressive expansion strategy. By 2023, the FCF will reach more than 40% of EBITDA
Cash Flow Statement (millions €) 2019 2020 2021 2022 2023 2024 2025 2026 2027
NOPLAT 44,9 54,3 65,6 68,8 70,2 72,4 75,1 78,8 84,0
Depreciations 16,4 16,4 15,1 15,2 15,2 15,2 15,2 15,2 15,2
Change in Working Capital -6,5 7,4 15,8 -8,4 0,8 3,4 3,8 4,3 4,9
CF from Operations 54,7 78,0 96,4 75,6 86,3 91,0 94,1 98,4 104,2
% Revenues 8% 10% 11% 9% 10% 11% 11% 11% 11%
Maintenance 22,8 24,0 25,7 26,6 27,2 27,8 28,6 29,5 30,5
Greenfields 0,7 45,3 8,2 - - - - - -
Acquisitions 44,7 - - - - - - - -
Internacionalization 8,1
CF from Investments 76,3 69,3 33,9 26,6 27,2 27,8 28,6 29,5 30,5
FCF before Financing -25,0 -22,4 15,9 50,6 42,2 41,1 42,7 45,1 48,6
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• LBO Model: in order to perform an accurate valuation of LNA, the LBO valuation was computed to optimize the fund’s
return and its credit statistics. Hence, through a multiple range of 15x – 9x, an IRR range of 24,8% - 26,4% was
estimated.
• DCF Gordon Growth Model: another option used to value the company from an intrinsic perspective was a discounted
cash flows analysis using the firm’s WACC, with a cost of debt of 3,74%*. Afterwards, a perpetuity was calculated in
2025 with terminal growth of 2%, corresponding to inflation.
• DCF Exit Multiple: a similar methodology was used but instead of using a perpetuity value, the sale of LNA in 2025 was
assumed, as well as the current exit multiple of the company - 11.8x.
• Precedent Transactions: 11 transactions were considered within the nursing home industry since 2004, with an average
announced value of €765 M.
• Historical Peers’ Multiples: an historical 7-year EV/EBITDA analysis of the peers was performed in order to mitigate
potential fluctuations in the current price driven by external market conditions. The peers considered were: Orpea,
Korian, Attendo, Philajalina and Mediclin AG.
• 2018 EV/EBITDA Multiples: the methodology used to perform the current valuation of LNA Santé was based on LNA’s and
its peers’ current value.
Football Field
The methodology applied focuses in diferent specifications of the market such as past similar transactions or historical valuations of comparable peers. It also takes into account
intrinsic valuations based on DCF and LBO analysis. It is expected that the exit will occur in 2023, matching the full-optimization of the strategies implemented with the ability to






To have a more accurate valuation of LNA Santé, different methods were used resulting in a multiple of 11.8x EBITDA, corresponding to a 
valuation of €591 M
25%-50%
50%-75%
* The computation of cost of debt was the following: total interests paid over the total debt
Sources: Bloomberg
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• Precedent transactions multiples were taken into consideration since it is important to
perceive the premiums of the transactions being carried in the industry. This analysis is
grounded on publicly available information of similar purchased companies in the past
years.
• The precedent transactions valuation yielded a multiple of 9.8x, which translates into a




















Year Min Median Max Average
2018 8.3x 11.42x 17.2x 11.55x
2017 9.7x 11.79x 20.6x 14,32x
2016 6.8x 13.39x 15.2x 12.32x
2015 5.3x 13.7x 33.9x 16.72x
2014 5.9x 13.08x 13.9x 10.94x
2013 9.3x 12.04x 13.4x 11.57x
2012 7.6x 11.58x 12.6x 10.60x
17.2x














• The trading comparables valuation relies on the idea that similar assets sell at similar
prices, based on market efficiency. Hence, in order to better grasp not only the current
market outlook but also the past, the median EV/EBITDA of the past 7 years of each
comparable company was used. The result averaged a multiple of 12.2x or €612 M.
• However, the 2018 EV/EBITDA multiples lay below the median of the past 7 years, at an
average multiple of 11.6x, corresponding to a valuation of €582 M.
Trading Comparables1 Precedent Transactions2
VALUATION|Trading Comparables and Precedent Transactions 
In 2018, trading comparables yielded an EV/EBITDA multiple of 11.6x, higher than the precedent transactions valuation - 9.8x. However, 
the trading comparables multiple of the past 7 years was the highest multiple – 12.2x
EV/EBITDA Multiples Per Year Suitable Deals for LNA Santé
Date Target Name Acquirer Name Total Value $M TV/EBITDA
2018 Civitas Solutions Inc Centerbridge Partners LP 1340 9.0x
2013 Orpea Canada Pension Plan 443 7.8x
2012 Curanum AG/Munich Korian SA 317 8.3x
2011 Rehabcare Group LLC Kindred Healthcare LLC 1277 7.8x
2010 Odyssey HealthCare Inc Gentiva Health Services Inc 891 10.2x
2007 21st Century Oncology Inc VCP I Inc 999 11.1x
2007 Surgical Care Affiliates Inc/Old TPG Capital LP/US 950 9.2x
2007 Symbion Inc/TN Stone Point Capital LLC 603 8.0x
2006 Horizon Health Corp Psychiatric Solutions Inc 413 12.1x
2005 Medidep SA Korian SA 217 12.1x
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CAPITAL STRUCTURE|Proposed Capital Structure
After a debt market analysis with Invesco, a bullet Term Loan A amounting to €276,3 M will be used, corresponding to 5.5x EBITDA
Debt Structure
LNA Santé’s debt will be repaid and the company will be refinanced. The new
capital structure will be based on a bullet senior debt issuance and total debt will
account for 45,3% of total sources. According to Invesco, the best debt structure
is as follows:
• A Term Loan A will be issued with 6 years to maturity (2024). It represents
5.5X EBITDA, or €276,3 M. It accrues interests of 3,75% a year (a banking fee of
1,5% was assumed for this issuance).
• A Revolving Credit Facility of €100 M will be opened in 2019 to finance the
expansion CAPEX and help face the debt interest expenses. The revolving will
be amortized in 6 yearly payment periods. A margin of 3,75% was assumed as
well as a Commitment fee of 30%.
Equity Structure
Total Equity will account for 54,7% of total sources corresponding to €334 M. It will be composed by:
• A Fixed Return Instrument amounting 48,2% of sources, or €294 M. This instrument will guarantee
an annual rate of return (PIK element) of 12,5%. The reason why the management will not co-
invest in the FRI is explained in the following slide.
• Ordinary Equity will be composed by 9% of sweet equity (€3,6 M) which represents approximately




With the help of Invesco it was made a thorough market analysis on the industry’s
practice of capital structure and the main outputs are the following:
• Commonly, a deal in this industry does not have a debt multiple above 6x
EBITDA due to a higher risk being associated to a higher debt multiple. Hence,
a comfortable 5.5x multiple was assumed as a result of Invesco’s advisory.
• The recommendation was to incur in a bank loan instead of issuing bonds to
accommodate a higher degree of flexibility.
• Currently, the market has not been using the capex facility financing.
Therefore, a revolving credit facility is the best alternative to finance the
expansion CAPEX needs.
• Furthermore, the margins for loans applied in the market correspond to a
floating rate of 3,75% plus the Euribor. Since the latter has been negative, it
does not have an impact on the rate calculation.
Sources of Funds € M x EBITDA % Uses € M
Senior debt EBITDA 2018 50
Term Loan A 276,3 5.5x 45,3% Multiple 11.8x
Term Loan B 0,0 0.0x 0,0% Enterprise Value 591
Term Loan C 0,0 0.0x 0,0%
Subordinated debt
Mezzanine 0,0 0.0x 0,0%
Total debt 276,3 5.5x 45,3%
Fixed Return Instrument 294,0 5.9x 48,2% Fees 3,3% 19,5
Ordinary Equity 40,0 0.8x 6,5%
Institutional Investor 36,4 Due Diligence 0,3% 1,8
Sweet Equity 3,6 9,0% Arrangement Fees 1,5% 8,9
Banking Fees 1,5% 8,9
Total Equity 334,0 6.6x 54,7%
Total sources 618,3 12,2 1 Total Uses 618,4
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CAPITAL STRUCTURE|Management Package
The management team will be entitled of 9% of ordinary shares after investing two times its salary. This will correspond to an Envy Ratio 
of 9
Management Ownership
• Currently, the Management team is composed by a CEO, CFO and COO that receive an annual wage compensation, shares from the company and a performance compensations. The
latter method of compensation is conditional to performance of the firm and corresponds to 1% of Net Income’s variation from one year to another. The current management is
composed by Jean-Paul Siret, the CEO Willy Siret, the COO and Damien Billard, the CFO and in 2018 each one has been attributed 2 500 shares as part of this package.
• This family business must have strong incentives to be aligned with the shareholders and hence, will invest in equity two times its salary corresponding to a sweet equity of €3,6 M.
• Furthermore, the management team will be reinforced by a set of new directors to ensure the well-functioning of the firm with the upcoming growth. These will have a compensation
scheme specially designed to ensure a great alignment with the fund. These directors are already key employees in the firm with great experience in the business (Annex 7).
• Wage compensation won’t change and each member of management will have 2x its salary in sweet equity, as mentioned before. This would represent 9% of ordinary shares.
• The management ownership will not be rolled-over given that the exit proceeds are sufficient to keep the management team on board with the fund’s mission. Additionally the re-
allocated directors are already well aligned with the new promotion and shift of function within the firm. Equity rollover are a common practice because it motivates the management
team to keep advising correctly the ongoing operations of the firm. Compensating the management in excess may lead to low efforts into running the business given that there is already
a good amount of money in their own bank accounts. Once again, in LNA’s case there is no need for co-investment for the aforementioned reasons.
€ Millions Ownership
Institutional Strip 334
    Fund 330
           Fixed Return Instrument 294
           Institutional Ords 36 91%
    Management 4
           Fixed Return Instrument
           Institutional Ords
Sweet Equity 4 9%
Total Equity 334 100%
EquityName Position Fixed Performance Shares Others Total
Existing Management
Jean-Paul Siret Chief Executive Officer 147 000 €   113 812 €              112 000 €      4 551 €      377 363 €        
Willy Siret Chief Operating Officer 137 000 €   113 812 €              112 000 €      2 537 €      365 349 €        
Damien Billard Chief Financial Officer 137 000 €   113 812 €              112 000 €      3 068 €      365 880 €        
Re-allocations
Christine Lioret Head of Growth 120 000 €   113 698 €              3 068 €      236 766 €        
Robert Dardanne Head of ALF 110 000 €   84 472 €               3 068 €      197 540 €        
Flavia Lorre Head of ACR 110 000 €   10 680 €               3 068 €      123 748 €        
Maux Roux Head of HC 110 000 €   18 546 €               3 068 €      131 614 €        
Total 1 798 261 €    
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Taking the course of Private Equity was the main driver for my decision to apply for this thesis. Doing a course of only three months was not enough to fulfill my hanger to know
more about Private Equity and hence, having the chance to spend quality time in building a project on this topic seemed the right opportunity. Furthermore, the opportunity to
work in a group answered my wishes for this semester.
This semester was important to consolidate many hard skills developed throughout the first year of masters such as research, data and financial analysis.
Furthermore, the last months were months of many challenges to be defeated. In a grup and as team it was needed to manage expectations, schedules, different points of view,
different working perspectives. There were many moments of contrasting ideas and opportunities to grow and learn from each other. For me, this thesis was a time to learn to be
more humble and to let myself be managed by an amazing team!
A final remark to Duarte, Gonçalo and Marta for teaching me so many things!
Maria Inês Costa e Sousa de Sena Esteves
